Visceral Adiposity Index Differences Between Subtypes of Polycystic Ovary Syndrome

NCT06358300 | Completed

• 1 other identifier: Usakpcos2
• Study Type: observational
• Target: 300
• Locations: 1 country
• Sites: 1

Brief Summary

We aimed to investigate visceral adiposity index (VAI) in patients with different phenotype of policystic ovary syndrome (PCOS) and to compare healthy controls.

Conditions

Visceral Adiposity Index; Polycystic Ovary Syndrome

Keywords

Polycystic ovary syndrome; Visceral Adiposity Index; PCOS Subtypes

Outcome Measures

Primary Outcomes (1)

• Visceral Adiposity Index Differences Between Subtypes of Polycystic Ovary Syndrome

  Since there are different metabolic effects in different subtypes of polycystic ovary syndrome; In this study we aimed to investigate whether there is a difference between VAI in different PCOS subtypes and the difference between these subtypes and the healthy group.

  Eight months

Study Arms (5)

Controls

Healthy controls between aged 18-35 years

PCOS Subtype 1

Hyperandrogenemia+oligoanovulation+PCO appearance on USG

PCOS Subtype 2

Hyperandrogenemia+oligoanovulation

PCOS Subtype 3

Hyperandrogenemia+PCO appearance on USG

PCOS Subtype 4

Oligoanovulation+PCO appearance on USG

Eligibility Criteria

• Age: 18 Years - 35 Years
• Sex: female
• Age Groups: Adult (18-64)
• Sampling Method: Probability Sample

Study Population

Woman aged between 18 and 35, age-matched between groups, diagnosed with PCOS and without a known cancer diagnosis, liver and kidney failure, not taking medications that would affect HDL, TG levels and insulin resistance and without active infection.

You may qualify if:

• Patients who applied for reasons such as hair growth, acne, menstrual irregularity or infertility and were diagnosed with PCOS after examination, biochemical, hormonal and sonographic tests,
• Female patients between the ages of 18-35,
• Patients without known cancer, liver or kidney failure,
• Patients who do not take medications that will affect HDL, TG levels and insulin resistance,
• Female patients without active infection will be included. -

You may not qualify if:

• Female patients under eighteen years of age and \>35 years of age,
• Patients with known cancer, liver and kidney failure,
• Patients taking medications that will affect HDL, TG levels and insulin resistance,
• Patients with active infection will not be included in the study. -

Sponsors & Collaborators

• Uşak University: lead

Study Sites (1)

Usak Training and Research Hospital

Uşak, 64100, Turkey (Türkiye)

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

After 8-12 hours of fasting, 2-3 ml of blood will be taken for serum HDL and TG measurement. Blood will be centrifuged and frozen at -70 °C.

MeSH Terms

Conditions

Polycystic Ovary Syndrome

Condition Hierarchy (Ancestors)

Ovarian Cysts; Cysts; Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases; Gonadal Disorders; Endocrine System Diseases

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Target Duration: 16 Months
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 4, 2024
• First Posted: April 10, 2024
• Study Start: January 1, 2022
• Primary Completion: September 1, 2022
• Study Completion: July 20, 2023
• Last Updated: April 10, 2024

Record last verified: 2024-04

Locations

TU (1)